Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Galunisertib + Nivolumab in Advanced Solid Tumors, NSCLC, and HCC
NCT02423343Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jan 2015
- Primary completion
- Dec 2018
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of galunisertib in solid tumor, non-small cell lung cancer (NSCLC), hepatocellular carcinoma (HCC), sponsored by Eli Lilly and Company. Started Jan 2015; status: completed.
02
Drugs
galunisertib
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT02423343.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02423343.